Stanford Cancer Institute

Cancer Cell Therapy

Classical Hodgkin's Lymphoma (cHL)

>12-75 Years

Relapsed or Refractory CD30 Positive Classical Hodgkin Lymphoma

CCT5040
Phase II CD30.CAR-T in Adult & Pediatric Relapsed/Refractory CD30 Positive Classical Hodgkin Lymphoma

PI: Arai
Sponsor: Pending

KEY

Pending
Open for Enrollment
Observational Study

Optional Path
Trial Posting

Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu

Version Date: 11 Sep 2020